

## Idaho Pharmacy And Therapeutics Committee

August 21, 2009



## :: Antidepressants, SSRIs



Brand Name	Current Rx	Current Market Share	Current PDL Status
CITALOPRAM (ORAL)	3,880	22.2%	PDL
FLUOXETINE (ORAL)	4,643	26.6%	PDL
FLUVOXAMINE (ORAL)	225	1.3%	PDL
LEXAPRO (ORAL)	2,562	14.7%	NPD
LUVOX CR (ORAL)	15	0.1%	NPD
PAROXETINE (ORAL)	912	5.2%	NPD
PAROXETINE CR (ORAL)	290	1.7%	NPD
PEXEVA (ORAL)	1	0.0%	NPD
PROZAC WEEKLY (ORAL)	1	0.0%	NPD
SERTRALINE (ORAL)	4,957	28.3%	PDL



## :: Antidepressants, Other (1 of 2)



Brand Name	Current Rx	Current Market Share	Current PDL Status
APLENZIN (ORAL)	1	0.0%	NPD
BUPROPION (ORAL)	212	2.0%	PDL
BUPROPION SR (ORAL)	1,256	11.9%	PDL
BUPROPION XL (ORAL)	2,403	22.7%	PDL
CYMBALTA (ORAL)	2,381	22.5%	NPD
EFFEXOR XR (ORAL)	2,798	26.5%	PDL
EMSAM (TRANSDERMAL)	5	0.0%	NPD
MARPLAN (ORAL)	1	0.0%	NR
MIRTAZAPINE (ORAL)	1,225	11.6%	PDL
NARDIL (ORAL)	2	0.0%	NR



## :: Antidepressants, Other (2 of 2)



Brand Name	Current Rx	Current Market Share	Current PDL Status
NEFAZODONE (ORAL)	16	0.2%	NPD
PARNATE (ORAL)	1	0.0%	NR
PRISTIQ (ORAL)	87	0.8%	NPD
TRANYLCYPROMINE (ORAL)	1	0.0%	NR
TRAZODONE (ORAL)	1	0.0%	NR
VENLAFAXINE (ORAL)	108	1.0%	NPD
VENLAFAXINE ER (ORAL)	68	0.6%	NPD
WELLBUTRIN XL (ORAL)	-	0.0%	NPD





## Stimulants and Related Agents (1 of 2)



Brand Name	Current Rx	Current Market Share	Current PDL Status
ADDERALL XR (ORAL)	3,361	18.3%	PDL
AMPHETAMINE SALT COMBO (ORAL)	991	5.4%	PDL
AMPHETAMINE SALT COMBO ER (ORAL)	1	0.0%	NPD
CONCERTA (ORAL)	5,765	31.5%	PDL
DAYTRANA (TRANSDERMAL)	133	0.7%	NPD
DESOXYN (ORAL)	5	0.0%	NPD
DEXMETHYLPHENIDATE (ORAL)	269	1.5%	PDL
DEXTROAMPHETAMINE (ORAL)	184	1.0%	PDL
FOCALIN (ORAL)	154	0.8%	PDL
FOCALIN XR (ORAL)	1,403	7.7%	PDL





## Stimulants and Related Agents (2 of 2)



Brand Name	Current Rx	Current Market Share	Current PDL Status
METADATE CD (ORAL)	418	2.3%	PDL
METHYLPHENIDATE (ORAL)	1,339	7.3%	PDL
METHYLPHENIDATE ER (ORAL)	278	1.5%	PDL
PROCENTRA (ORAL)	-	0.0%	NPD
PROVIGIL (ORAL)	130	0.7%	NPD
RITALIN LA (ORAL)	283	1.5%	NPD
STRATTERA (ORAL)	2,441	13.3%	NPD
VYVANSE (ORAL)	1,167	6.4%	PDL





#### >> New Products/Indications



#### **Products**

- Procentra dextroamphetamine oral solution
- Nuvigil armodafinil
  - Racemic mixture (modafinil is R-enantiomer)
  - Same indications as modafinil except ≥17 y/o instead of ≥16 y/o
- **Indications** 
  - Vyvanse ADHD in adults





#### Clinical Trials – armodafanil (OSAHS)



- Two double blind parallel group trials
- 658 patients with OSAHS and compliant with **CPAP**
- Treatment groups armodafinil 150 or 250 mg/day or placebo X12 weeks
- Results
  - Significantly more patients receiving active treatment showed improvement in CGI





#### Clinical Trials – armodafanil (narcolepsy)



- Double blind RCT 196 patients
- Treatment groups armodafinil 150 or 250 mg/day or placebo
- Results
  - Significantly more patients receiving active treatment showed improvement in CGI
  - No difference in nighttime sleep with polysomnography





### :: Clinical Trials – armodafanil (SWSD)



- Double blind RCT 254 patients
- Treatment groups armodafinil 150 mg/day or placebo X12 weeks
- Results
  - Active treatment significantly prolonged time to sleep onset, improvement in CGI





#### Clinical Trials – lisdexamfetamine in adults



- Double blind RCT 420 adults with ADHD
- Treatment groups lisdexamfetamine 30, 50 or 70 mg or placebo daily X4 weeks
- Results significant improvements in ADHD symptoms (investigator rated) with active treatment







- NICE (2008) ADHD
  - Children and young adults Drug treatment as first line therapy only with severe ADHD and impairment diagnosed by specialist
  - Adults start drug treatment in adults with moderate to severe impairment diagnosed by specialist
  - First line agents MPH, atomoxetine, dexamphetamine







Brand Name	Current Rx	Current Market Share	Current PDL Status
APIDRA (SUBCUTANE.)	31	0.7%	NPD
APIDRA PENS (SUBCUTANE.)	6	0.1%	NPD
HUMALOG (SUBCUTANE.)	584	13.5%	PDL
HUMALOG MIX (SUBCUTANE.)	58	1.3%	PDL
HUMALOG MIX PENS (SUBCUTANE.)	31	0.7%	PDL
HUMALOG PENS (SUBCUTANE.)	257	5.9%	PDL
HUMULIN (SUBCUTANE.)	276	6.4%	PDL







Brand Name	Current Rx	Current Market Share	Current PDL Status
HUMULIN PENS (SUBCUTANE.)	16	0.4%	PDL
LANTUS (SUBCUTANE.)	1,311	30.3%	PDL
LANTUS PENS (SUBCUTANE.)	468	10.8%	PDL
LEVEMIR (SUBCUTANE.)	90	2.1%	PDL
LEVEMIR PENS (SUBCUTANE.)	133	3.1%	PDL
NOVOLIN (SUBCUTANE.)	161	3.7%	PDL







Brand Name	Current Rx	Current Market Share	Current PDL Status
NOVOLIN PENS (SUBCUTANE.)	10	0.2%	PDL
NOVOLOG (SUBCUTANE.)	445	10.3%	PDL
NOVOLOG MIX 70/30 (SUBCUTANE.)	45	1.0%	PDL
NOVOLOG MIX 70/30 PENS (SUBCUTANE.)	68	1.6%	PDL
NOVOLOG PENS (SUBCUTANE.)	333	7.7%	PDL







- Insulin glulisine (Apidra) children <u>></u>4 yr
- Open label study 572 children and adolescents with type 1 DM
- Treatment groups insulin glulisine or lispro 0-15 min pre-meal with insulin glargine QD or NPH BID as basal insulin
  - ~70% in each group received insulin glargine as part of basalprandial regimen

#### Results

- No significant difference in change in HbA1c (insulin glulisine +0.10%, lispro +0.16%)
- No difference in postprandial glycemic control
- Hypoglycemia insulin glulisine 7.2%, lispro 72% (p=NS)







- Insulin glulisine (Apidra)
  - SoloStar pen (3 ml prefilled)
- Insulin detemir (Levemir)
  - Innolet (3 ml prefilled)
- FlexPen redesigned
  - Less force required, limits maximum dose to amount of insulin left in pen





### :: Clinical Trials - Type 2 DM



- Open label study 418 patients inadequately controlled on oral hypoglycemics
- Treatment groups insulin glargine (Lantus) QD or lispro (Humalog) TID X44 weeks
- Results
  - Primary endpoint change in HbA1c from baseline no difference
  - Secondary endpoint percentage of patients with HbA1c <7%</li>
  - Insulin glargine greater mean change in FPG (-4.3 vs -1.8 mmol/L; p<0.0001) and nocturnal BG (-3.3 vs -2.6 mmol/L; p=0.0041
  - Hypoglycemia insulin glargine 5.2 events per patient-yr vs lispro 24.0 events (p<0.001)
  - Weight gain no difference





### Meta-Analysis – Type 2 DM



- 45 clinical trials of 14,603 patients
- Premixed insulin analogues vs long acting insulin analogues
  - Premixed insulin analogues more effective than in reducing postprandial glucose levels and HbA1c
  - Long acting insulin analogues more effective in reducing FPG; less hypoglycemia and weight gain
- Premixed insulin analogues vs premixed human insulin
  - Similar decreasing FPG and HbA1c; hypoglycmiea
  - Analogues more effective in decreasing PPG
- Premixed insulin analogues vs non-insulin diabetic agents
  - Analogues more effective in decreasing FPG, PPG, HbA1c; higher incidence of hypoglycemia







Brand Name	Current Rx	Current Market Share	Current PDL Status
CREON (ORAL)	80	35.1%	PDL
PANCREASE MT (ORAL)	29	12.7%	PDL
PANCRECARB MS (ORAL)	15	6.6%	NPD
PANCRELIPASE (ORAL)	57	25.0%	PDL
ULTRASE (ORAL)	38	16.7%	PDL
VIOKASE (ORAL)	9	3.9%	PDL







- Creon pancreatic insufficiency
  - First approved under new guidelines
    - Requires approved NDAs by April 2010
  - Double blind placebo controlled crossover RCT 32 patients with CF
  - CFA (Coefficient of Fat Absorption) pancrelipase 89% vs placebo
     49%
  - Patients with AEs pancrelipase 50% vs placebo 71%





# BONE RESORPTION SUPPRESSION AND RELATED AGENTS 1 of 2



Brand Name	Current Rx	Current Market Share	Current PDL Status
ACTONEL (ORAL)	40	5.4%	PDL
ACTONEL W/CALCIUM (ORAL)	1	0.1%	NPD
ALENDRONATE TABLETS (ORAL)	575	77.1%	PDL
BONIVA (ORAL)	61	8.2%	NPD
CALCITONIN SALMON (NASAL)	9	1.2%	NPD





# BONE RESORPTION SUPPRESSION AND RELATED AGENTS 2 of 2



Brand Name	Current Rx	Current Market Share	Current PDL Status
DIDRONEL (ORAL)	1	0.1%	NPD
ETIDRONATE DISODIUM (ORAL)	1	0.1%	NPD
FORTEO (SUBCUTANE.)	13	1.7%	NPD
FORTICAL (NASAL)	11	1.5%	NPD
FOSAMAX PLUS D (ORAL)	1	0.1%	PDL
FOSAMAX SOLUTION (ORAL)	5	0.7%	PDL
MIACALCIN (NASAL)	28	3.8%	PDL







- Calcitonin-salmon generic Miacalcin
- Actonel
  - 75 mg tablets two days monthly
  - 150 mg tablets once monthly





#### **∴** • Guidelines – NOF 2008



All approved medications – possible options for prevention and/or treatment of osteoporosis







- Double blind non-inferiority RCT postmenopausal women with mean lumbar spine BMD-T = -2.5 to -5.0
- Treatment groups ibandronate 150 mg once monthly or alendronate 70 mg once weekly
- Primary endpoints change in BMD at one year
  - Mean lumbar spine ibandronate 5.1% vs alendronate 5.8%
  - Total hip ibandronate 2.9% vs alendronate 3.0%
  - Non-inferiority proven



#### Adherence – Daily vs Weekly bisphosphonate



Together, we can do more

- Claims data
  - Weekly alendronate 35 or 70 mg
  - Daily alendronate 5-10 mg or risedronate 5 mg
- Medication compliance
  - Weekly 69% vs Daily 58% (p=0.0001)
- Persistence
  - Weekly > daily
- Retention on treatment at 12 months
  - Weekly 44% vs daily 37% (p<0.0001)</li>





#### Adherence – Weekly vs Monthly risedronate



Together, we can do more.

- Claims data
- Compliance and persistence higher with weekly dosing







Brand Name	Current Rx	Current Market Share	Current PDL Status
ARICEPT / ARICEPT ODT (ORAL)	105	66.5%	PDL
COGNEX (ORAL)	1	0.6%	NPD
EXELON (ORAL)	2	1.3%	PDL
EXELON (TRANSDERM.)	1	0.6%	PDL
EXELON SOLUTION (ORAL)	1	0.6%	PDL
GALANTAMINE (ORAL)	1	0.6%	NPD
GALANTAMINE ER (ORAL)	1	0.6%	NPD
NAMENDA (ORAL)	46	29.1%	PDL





#### Guidelines – Treatment of dementia



- ACCP/AAFP (2008)
  - Decision to initiate trial of pharmacotherapy should be based on individual assessment
  - Urgent need for additional research







Brand Name	Current Rx	Current Market Share	Current PDL Status
ANDRODERM (TRANSDERM.)	25	36.2%	PDL
ANDROGEL (TRANSDERM.)	43	62.3%	PDL
TESTIM (TRANSDERM.)	1	1.4%	NPD







- Testosterone gel products
  - Eight reports of children experience AEs after unintended exposure through contact with individual being treated







No preferred method of TRT



#### **::** Newer Antiemetics



Brand Name	Current Rx	Current Market Share	Current PDL Status
ANZEMET (ORAL)	6	1.0%	NPD
CESAMET (ORAL)	1	0.2%	NPD
DRONABINOL (ORAL)	12	1.9%	NPD
EMEND (ORAL)	16	2.6%	PDL
GRANISETRON (ORAL)	6	1.0%	NPD
MARINOL (ORAL)	18	2.9%	NPD
ONDANSETRON / ODT (ORAL)	567	90.4%	PDL
SANCUSO (TRANSDERMAL)	1	0.2%	NPD





# HYPOGLYCEMICS, INCRETIN MIMETIC ENHANCERS



Brand Name	Current Rx	Current Market Share	Current PDL Status
BYETTA PENS (SUBCUTANE.)	233	50.8%	PDL
JANUMET (ORAL)	26	5.7%	NPD
JANUVIA (ORAL)	181	39.4%	NPD
SYMLIN (SUBCUTANE.)	7	1.5%	PDL
SYMLIN PENS (SUBCUTANE.)	12	2.6%	PDL



### :: Antipsychotics, Atypical



Brand Name	Current Rx	Current Market Share	Current PDL Status
ABILIFY (ORAL)	4,705	23.0%	ON
CLOZAPINE (ORAL)	473	2.3%	ON
FAZACLO (ORAL)	3	0.0%	NR
GEODON (IM)	5	0.0%	NR
GEODON (ORAL)	1,606	7.8%	ON
INVEGA (ORAL)	567	2.8%	ON
RISPERDAL (ORAL)	314	1.5%	NPD
RISPERDAL CONSTA (IM)	501	2.4%	NR
RISPERIDONE (ORAL)	4,380	21.4%	ON
SEROQUEL (ORAL)	5,847	28.5%	ON
SEROQUEL XR (ORAL)	71	0.3%	ON
SYMBYAX (ORAL)	68	0.3%	ON
ZYPREXA (IM)	1	0.0%	NR
ZYPREXA (ORAL)	1,946	9.5%	ON
Restricted Access – Proprietary and/or Confidential.  Do not disseminate or copy without approval.			H & WELFARE

## :: Antipsychotics, Conventional



Brand Name	Current Rx	Current Mark et Share	Current PDL Statu s
AMITRIPTYLINE / PERPHENAZINE (ORAL)	6	0.5%	NR
CHLORPROMAZINE (ORAL)	235	19.6%	NR
FLUPHENAZINE (ORAL)	173	14.4%	NR
FLUPHENAZINE DECANOATE (IM)	47	3.9%	NR
HALOPERIDOL (ORAL)	379	31.5%	NR
HALOPERIDOL DECANOATE (IM)	52	4.3%	NR
MOBAN (ORAL)	12	1.0%	NR
PERPHENAZINE (ORAL)	106	8.8%	NR
THIORIDAZINE (ORAL)	64	5.3%	NR
THIOTHIXENE (ORAL)	93	7.7%	NR
TRIFLUOPERAZINE (ORAL)	35	2.9%	NR







Brand Name	Current Rx	Current Market Share	Current PDL Status
AMEVIVE (INJECTION)	1	0.5%	NPD
CIMZIA (INJECTION)	1	0.5%	NPD
ENBREL (INJECTION)	124	56.4%	PDL
HUMIRA (INJECTION)	90	40.9%	PDL
KINERET (INJECTION)	2	0.9%	PDL
ORENCIA (INJECTION)	1	0.5%	NPD
REMICADE (INJECTION)	1	0.5%	NPD







- Cimzia certolizumab pegol
- Indication Crohn's disease in adults
- Warnings similar to other TNF blockers







- Raptiva (efalizumab)
  - Due to PML





#### :: Treatment Guidelines – RA



#### ACR 2008 Recommendations

- early RA only when high disease activity and patient is DMARDnaive – TNF blocker + MTX
- Moderate to long duration RA TNF blockers in patients with unsatisfactory response to MTX
- abatacept (Orencia) and rituximab (Rituxan) reserve for patients with at least moderate disease activity and poor disease prognosis following treatment with MTX or other DMARDs





#### Treatment Guidelines – Psoriasis/Psoriatic A



#### AAD 2008 Recommendations

- Mild to moderate PsA NSAIDs and/or intra-articular corticosteroid injections
- Significant PsA DMARDs, including MTX, plus biologic agents
- Plaque psoriasis MTX, cyclosporine, acitretin, adalimumab, etanercept, infliximab







- Double blind RCT 190 patient 6-17 yr with active JIA in at least five joints with inadequate response or intolerance to a DMARD
- Open label abatacept X4 mos with responders (123/170) randomized to abatacept or placebo
- Results
  - Flares abatacept 20% vs placebo 53% (p=0.0003)
  - Patients with AEs abatacept 62% vs placebo 55%







- Double blind RCT 431 adults
- Treatment groups MTX +
  - abatacept q4w, infliximab q8w or placebo q4w
- Results
  - Change in Disease Activity Score (based on ESR) both active treatments more effective than placebo
  - ACR20 (Day 197) abatacept 67%, infliximab 59%, placebo
     42%
    - Difference maintained through one year
  - Remission abatacept 18% vs infliximab 12%
  - AEs and DC due to AEs less common with abatacept







- TEMPO double blind RCT 686 patients
- Treatment groups etanercept twice weekly, MTX or combination
- Results
  - TSS combination superior to monotherapy in slowing joint damage
  - ACR combination superior to monotherapy





#### :: Systematic Review - RA



- 13 studies of 7087 patients
  - adalimumab, etanercept, infliximab
- Efficacy outcomes (ACR 20, 50, 70) no difference
- AEs patients receiving etanercept less likely to drop out because of AEs





#### : Clinical Trials - certolizumab



- Double blind RCT 662 patients with moderate to severe Crohn's disease
- Treatment groups certolizumab or placebo X26 weeks
- Results
  - Response rates certolizumab 35% vs placebo 27% (p=0.02)
  - Remission rates no significant difference





#### : Clinical Trials - certolizumab



- PRECISE-2 double blind RCT 668 adults with moderate to severe Crohn's disease
- Treatment groups
  - certolizumab open label X4 weeks
  - Responders randomized to certolizumab or placebo X26 weeks
- Results
  - Response at week 26 certolizumab 62% vs placebo 34% (p<0.001)
  - Remission at week 26 certolizumab 48% vs placebo 29% (p<0.001)





### :: Meta-Analysis – Crohn's Disease



- 14 clinical trials nearly 4000 patients treated with adalimumab, certolizumab or infliximab
- TNF blockers effective
  - for induction of remission at week 4 (16 vs 6%; p<0.001)</li>
  - For maintenance or remission at weeks 20-30 (23 vs 8%; p < 0.001)





### :: Clinical Trials – plaque psoriasis



- Double blind RCT 507 adults with chronic plaque psorasis
- Treatment groups alefacept or placebo X12 weeks
- Results
  - PASI 75 response alefacept 15 mg 21% vs alefacept 10 mg 5% vs placebo 5% (p<0.001 compared to higher dose)





### Systematic Review – Psoriasis



- 24 clinical trials of 9400 patients with moderate to severe psoriasis
- Efficacy outcome measure PASI75 at weeks 8to 16
  - Infliximab 77% (95%Cl 72-81%)
  - Adalimumab 64% (95%CI 61-68%)
  - Etanercept 50 mg 44% (95%CI 40-48%)
  - Etanercept 25 mg 30% (95%Cl 25-35%)





#### Systematic Review – Plaque Psoriasis



- 16 studies of nearly 8000 patients
- Efficacy outcome PASI75 after 10-14 weeks
  - Infliximab NNT = 2
  - Etanercept NNT = 3
  - Alefacept NNT = 8







- 6 RCTs of 982 patients
  - adalimumab, etanercept, infliximab
- Results
  - ACR 20, 50, 70 no difference
  - AEs no difference
  - Serious AEs no difference





# PLATELET AGGREGATION INHIBITORS



Brand Name	Current Rx	Current Market Share	Current PDL Status
AGGRENOX (ORAL)	46	7.1%	PDL
DIPYRIDAMOLE (ORAL)	6	0.9%	PDL
PLAVIX (ORAL)	600	92.0%	PDL
TICLOPIDINE (ORAL)	-	0.0%	NPD





### Systematic Review – Psoriasis



- 24 clinical trials of 9400 patients with moderate to severe psoriasis
- Efficacy outcome measure PASI75 at weeks 8to 16
  - Infliximab 77% (95%Cl 72-81%)
  - Adalimumab 64% (95%CI 61-68%)
  - Etanercept 50 mg 44% (95%CI 40-48%)
  - Etanercept 25 mg 30% (95%Cl 25-35%)





#### Systematic Review – Plaque Psoriasis



- 16 studies of nearly 8000 patients
- Efficacy outcome PASI75 after 10-14 weeks
  - Infliximab NNT = 2
  - Etanercept NNT = 3
  - Alefacept NNT = 8







- 6 RCTs of 982 patients
  - adalimumab, etanercept, infliximab
- Results
  - ACR 20, 50, 70 no difference
  - AEs no difference
  - Serious AEs no difference







- Variability in response to clopidogrel
  - Pre-existing variability in platelet response to ADP, generic variability, drug interactions
  - CYP2C19 variant
    - Associated with recurrent thrombotic events in patients taking clopidogrel
    - Occurrence related to ancestry
      - European 30%
      - African 40%
      - Asian 50%







- Studies reporting increased risk of CV events including MI and death or increased platelet reactivity in patients receiving PPIs + clopidogrel
  - No evidence with H2RAs or antacids
  - PPIS may decrease conversion of clopidogrel to active metabolite





#### :: Guidelines – ischemic stroke



- **ACCP 2008** 
  - Acute ischemic stroke ASA
  - Long term prevention in patients with noncardioembolic stroke or TIA – ASA, ASA/dipyridamole ER, clopidogrel
    - ASA/dipyridamole or clopidogrel recommended over ASA





#### :: Guidelines - STEMI



#### **ACCP 2008**

 ASA indefinitely + clopidogrel X28 days (if fibrinolytic therapy without reperfusion) or up to one year if no stents





#### :: Guidelines - ACS



- **ACCP 2008** 
  - ASA indefinitely + clopidogrel up to 12 months





#### :: Guidelines - Stents



- **ACCP 2008** 
  - Bare metal or drug-eluting ASA + clopidogrel for at least 1 year
    - Indefinite suggested if no bleeding or tolerability





#### Clinical Trials – Secondary stroke prevention



PRoFESS – double blind noninferiority RCT of 20,332 patients with noncardioembolic stroke in previous 120 days

- Treatment groups ASA/dipyridamole ER or clopidogrel X2.5 years
- Results no difference in incidence of recurrent strokes did not meet criteria for noninferiority
- Major hemorrhagic events, ICH higher with ASA/dipyridamole ER
- Net risk of recurrent stroke or hemorrhagic events similar in each group





1 of 2

### ANTIPARKINSONS AGENTS



Together, we can do more.

Brand Name	Current Rx	Current Market Share	Current PDL Status
AZILECT (ORAL)	6	0.2%	NPD
BENZTROPINE (ORAL)	1,221	45.5%	PDL
CARBIDOPA / LEVODOPA (ORAL)	218	8.1%	PDL
CARBIDOPA / LEVODOPA ODT (ORAL)	1	0.0%	PDL
COMTAN (ORAL)	1	0.0%	NPD
MIRAPEX (ORAL)	220	8.2%	NPD





2 of 2

## :: ANTIPARKINSONS AGENTS



Together, we can do more.

Brand Name	Current Rx	Current Market Share	Current PDL Status
REQUIP XL (ORAL)	8	0.3%	NPD
ROPINIROLE (ORAL)	674	25.1%	PDL
SELEGILINE (ORAL)	3	0.1%	PDL
STALEVO (ORAL)	7	0.3%	PDL
TASMAR (ORAL)	1	0.0%	NPD
TRIHEXYPHENIDYL (ORAL)	323	12.0%	PDL
ZELAPAR (ORAL)	1	0.0%	NPD







 Stalevo – increased urges (gambling, sexual, etc.) with inability to control







- Double blind RCT 687 patients
- Treatment groups rasagiline (Azilect), entacapone (Comtan) or placebo
- Results active treatments similar in all respects





## :: ANALGESICS-ANESTHETICS, TOPICAL



Brand Name	Current Rx	Current Market Share	Current PDL Status
FLECTOR (TOPICAL)	2	0.4%	NPD
LIDODERM (TOPICAL)	481	98.2%	PDL
VOLTAREN (TOPICAL)	7	1.4%	NPD







No significant new clinical information







Brand Name	Current Rx	Current Market Share	Current PDL Status
ARTHROTEC (ORAL)	59	0.6%	NPD
CELEBREX (ORAL)	384	3.7%	NPD
DICLOFENAC (ORAL)	640	6.2%	PDL
ETODOLAC (ORAL)	532	5.2%	PDL
FENOPROFEN (ORAL)	1	0.0%	PDL
FLURBIPROFEN (ORAL)	7	0.1%	PDL







Brand Name	Current Rx	Current Market Share	Current PDL Status
IBUPROFEN OTC (ORAL)	1	0.0%	PDL
IBUPROFEN RX (ORAL)	4,535	44.0%	PDL
INDOMETHACIN (ORAL/RECTAL)	143	1.4%	PDL
KETOPROFEN (ORAL)	12	0.1%	NPD
KETOROLAC (ORAL)	143	1.4%	PDL
MECLOFENAMATE (ORAL)	1	0.0%	PDL







Brand Name	Current Rx	Current Market Share	Current PDL Status
MELOXICAM (ORAL)	1,169	11.4%	PDL
NABUMETONE (ORAL)	243	2.4%	PDL
NAPROXEN RX (ORAL)	2,012	19.5%	PDL
OXAPROZIN (ORAL)	98	1.0%	PDL
PIROXICAM (ORAL)	246	2.4%	PDL
SULINDAC (ORAL)	70	0.7%	PDL
TOLMETIN (ORAL)	1	0.0%	NPD





#### :: Guidelines – ACC/ACG/AHA



Prophylaxis of NSAID and ASA-associated gastric injury - PPIs preferred over misoprostol, sucralfate and other gastroprotective agents



### :: Ophthalmic Antibiotics



Brand Name	Current Rx	Current Market Share	Current PDL Status
AZASITE (OPHTHALMIC)	5	0.2%	NPD
BACITRACIN (OPHTHALMIC)	1	0.0%	NR
BACITRACIN/POLYMYXIN (OPHTHALMIC)	10	0.3%	NR
CILOXAN OINTMENT (OPHTHALMIC)	1	0.0%	NPD
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	81	2.8%	PDL
ERYTHROMYCIN (OPHTHALMIC)	446	15.6%	PDL
GENTAMICIN (OPHTHALMIC)	425	14.8%	NR
IQUIX (OPHTHALMIC)	1	0.0%	PDL
NATACYN (OPHTHALMIC)	1	0.0%	NR



#### :: Ophthalmic Antibiotics



Brand Name	Current Rx	Current Market Share	Current PDL Status
NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	1	0.0%	NR
OFLOXACIN (OPHTHALMIC)	31	1.1%	PDL
QUIXIN (OPHTHALMIC)	1	0.0%	NPD
SULFACETAMIDE (OPHTHALMIC)	256	8.9%	NR
TOBRAMYCIN (OPHTHALMIC)	284	9.9%	NR
TOBREX OINTMENT (OPHTHALMIC)	20	0.7%	NR
TRIPLE ANTIBIOTIC (OPHTHALMIC)	46	1.6%	NR
VIGAMOX (OPHTHALMIC)	1,227	42.9%	PDL
ZYMAR (OPHTHALMIC)	25	0.9%	PDL





#### :: Therapeutic Drug Class - Change



- Ophthalmic Fluoroquinolones expanded to include all antibiotics
- Non-quinolone antibiotics previously reviewed







- Besivance (besifloxacin)
  - Advanced ("5<sup>th</sup>") generation FQ
  - 0.6% suspension
  - DuraSite mucoadhesive delivery system
  - Indication bacterial conjunctivitis in patients ≥1 yr
  - Dosage TID X7 days (like Vigamox)
  - AEs well tolerated no burning reported







- Double blind RCT patients 1-98 yr
- Treatment groups besifloxacin or vehicle TID X5 days
- Results
  - Clinical resolution besifloxacin 45% vs vehicle 33% (difference 12%; 95%Cl of difference 3-22%)
  - Microbiologic eradication besifloxacin 91% vs vehicle 60% (difference 31%; 95%Cl of difference 23-40%)







- RCT 56 patients <18 yr with bacterial conjunctivitis</li>
- Treatment groups polymyxin B/trimethoprim QID or moxifloxacin (Vigamox) TID X7 days
- Primary outcome complete resolution at 48 hours
  - Moxifloxacin 81%
  - Polymyxin B/trimethoprim 44% (p=0.001)
- AEs none reported





# .. OPHTHALMICS, GLAUCOMA AGENTS 1 of 4



Brand Name	Current Rx	Current Market Share	Current PDL Status
ALPHAGAN P (OPHTHALMIC)	67	16.2%	PDL
AZOPT (OPHTHALMIC)	14	3.4%	PDL
BETAXOLOL (OPHTHALMIC)	1	0.2%	PDL
BETIMOL (OPHTHALMIC)	6	1.4%	PDL
BETOPTIC S (OPHTHALMIC)	5	1.2%	PDL
BRIMONIDINE (OPHTHALMIC)	1	0.2%	PDL
CARTEOLOL (OPHTHALMIC)	1	0.2%	PDL





# ... OPHTHALMICS, GLAUCOMA AGENTS 2 of 4



Brand Name	Current Rx	Current Market Share	Current PDL Status
COMBIGAN (OPHTHALMIC)	16	3.9%	PDL
COSOPT (OPHTHALMIC)	18	4.3%	PDL
DORZOLAMIDE (OPHTHALMIC)	1	0.2%	NPD
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	13	3.1%	NPD
ISTALOL (OPHTHALMIC)	3	0.7%	PDL
LEVOBUNOLOL (OPHTHALMIC)	1	0.2%	PDL
LUMIGAN (OPHTHALMIC)	36	8.6%	PDL
Restricted Access – Proprietary and/or Confider  Do not disseminate or copy without approval.	ntial.	HEALTH	& WELFARE



# ... OPHTHALMICS, GLAUCOMA AGENTS 3 of 4



Brand Name	Current Rx	Current Market Share	Current PDL Status
METIPRANOLOL (OPHTHALMIC)	1	0.2%	PDL
PILOCARPINE (OPHTHALMIC)	6	1.4%	PDL
PROPINE (OPHTHALMIC)	1	0.2%	NPD
TIMOLOL (OPHTHALMIC)	42	10.1%	PDL
TRAVATAN / TRAVATAN Z (OPHTHALMIC)	79	19.1%	PDL
TRUSOPT (OPHTHALMIC)	4	1.0%	PDL
XALATAN (OPHTHALMIC)	98	23.7%	PDL









- Double blind non-inferiority RCT 207 patients with glaucoma or ocular HPT treated with brimonidine 0.15% BID
- Treatment groups brimonidine 0.1% or 0.15% BID X12 months
- Results
  - IOP lowering lower strength not inferior
  - AEs no difference





## OPHTHALMICS, ANTI-INFLAMMATORIES 1 of 3



Brand Name	Current Rx	Current Market Share	Current PDL Status
ACULAR LS (OPHTHALMIC)	8	6.7%	PDL
ACULAR PF (OPHTHALMIC)	1	0.8%	PDL
DEXAMETHASONE (OPHTHALMIC)	4	3.3%	NR
DICLOFENAC (OPHTHALMIC)	1	0.8%	NPD
DUREZOL (OPHTHALMIC)	1	0.8%	NR
FLAREX (OPHTHALMIC)	1	0.8%	NR
FLUOROMETHOLONE (OPHTHALMIC)	24	20.0%	NR





# OPHTHALMICS, ANTI-INFLAMMATORIES 2 of 3



Brand Name	Current Rx	Current Market Share	Current PDL Status
FLURBIPROFEN (OPHTHALMIC)	1	0.8%	PDL
FML FORTE (OPHTHALMIC)	1	0.8%	NR
FML S.O.P. (OPHTHALMIC)	1	0.8%	NR
LOTEMAX (OPHTHALMIC)	52	43.3%	NR
MAXIDEX (OPHTHALMIC)	1	0.8%	NR
NEVANAC (OPHTHALMIC)	12	10.0%	PDL
PRED MILD (OPHTHALMIC)	1	0.8%	NR





### OPHTHALMICS, ANTI-INFLAMMATORIES 3 of 3



Brand Name	Current Rx	Current Market Share	Current PDL Status
RETISERT (INTRAOCULR)	1	0.8%	NR
TRIESENCE (INTRAOCULR)	1	0.8%	NR
VEXOL (OPHTHALMIC)	1	0.8%	NR
XIBROM (OPHTHALMIC)	8	6.7%	PDL





#### :: Therapeutic Drug Class - Change



- Ophthalmic NSAIDs expanded to include all anti-inflammatories (i.e., steroids)
- Most steroids previously reviewed





#### >> New Product - Durezol



- difluprednate 0.05% solution
- Indication treatment of inflammation and pain associated with ocular surgery
- QID X2 wks post-op, then BID X1 wk, then taper
- Clinical Trials 2 double blind RCTs
  - difluprednate or vehicle BID or QID X14 days
  - Anterior chamber cell clearing difluprednate 22-41% vs vehicle 7-11% (p<0.01)
  - Pain free subjects difluprednate 58-63% vs vehicle 27-35% (p<0.01)





#### >> New Product - Triesence



- triamcinolone acetonide intravitreal
- Indications sympathetic ophthalmia, temporal arteritis, uveitis, other inflammatory conditions unresponsive to topical steroids, visualization during vitrectomy
- Pregnancy category D (others C)

